O'Reilly D, Hanscombe O, O'Hare P
Marie Curie Research Institute, The Chart, Oxted, Surrey, UK.
EMBO J. 1997 May 1;16(9):2420-30. doi: 10.1093/emboj/16.9.2420.
We show that VP16 is phosphorylated by cellular kinases in vivo and in vitro and map the major sites of phosphorylation to be on serines towards the C-terminus, downstream of position 370 in both cases. Deletion of the acidic activation domain had no effect on phosphorylation, refining the sites to between position 370 and 411. Within VP16, the C-terminal boundary for complex formation with Oct-1 and HCF lies at position 388, and between 370 and 388 lies one serine, at position 375. This is a consensus casein kinase II (CKII) site and, using purified wild-type and mutant proteins, we show that it is the main CKII site in the body of the N-terminal complex-forming region. This site is also phosphorylated in nuclear extracts. Although other sites, mainly Ser411, are also phosphorylated by nuclear kinase(s), the single substitution of Ser375 to alanine abolishes CKII phosphorylation in vitro and virtually eliminates complex formation. This serine lies in a surface-exposed region of VP16 and, although complex formation is disrupted, other activities of the mutant are unaffected. Ser375 is also required in vivo where substitution to alanine abolishes transactivation, while replacement with threonine restores normal levels of activity.
我们发现,在体内和体外,VP16均会被细胞激酶磷酸化,且主要磷酸化位点位于两种情况下C端的丝氨酸上,在370位下游。酸性激活域的缺失对磷酸化无影响,从而将位点细化至370位和411位之间。在VP16中,与Oct-1和HCF形成复合物的C端边界位于388位,在370位和388位之间有一个丝氨酸,位于375位。这是一个共有酪蛋白激酶II(CKII)位点,通过使用纯化的野生型和突变蛋白,我们发现它是N端复合物形成区域主体中的主要CKII位点。该位点在核提取物中也会被磷酸化。虽然其他位点,主要是Ser411,也会被核激酶磷酸化,但将Ser375单突变为丙氨酸会消除体外的CKII磷酸化,并几乎消除复合物的形成。该丝氨酸位于VP16的表面暴露区域,虽然复合物形成被破坏,但突变体的其他活性不受影响。在体内,Ser375也是必需的,将其突变为丙氨酸会消除反式激活,而用苏氨酸替代则可恢复正常水平的活性。